BioCryst Pharmaceuticals, Inc.
HUMAN PLASMA KALLIKREIN INHIBITORS

Last updated:

Abstract:

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

13 Jul 2021

Issue date:

31 Mar 2022